Descripción del proyecto
Mejora del riesgo de predicción del cáncer de cuello uterino
El virus del papiloma humano (VPH) es responsable del cáncer cervicouterino, el cuarto tipo de neoplasia más prevalente en mujeres. En todo el mundo se están utilizando análisis de ADN como prueba de cribado para detectar el VPH en citologías cervicales. Sin embargo, el análisis del ADN por sí solo no permite identificar los casos de infección que progresarán para dar lugar a un cáncer frente a aquellos que se revertirán de manera espontánea. El proyecto financiado con fondos europeos OncoPredict ha desarrollado un dispositivo de diagnóstico capaz de detectar los genotipos del VPH de alto riesgo. Los datos se combinan con otros biomarcadores para estratificar de forma más precisa a las mujeres en riesgo de desarrollar cáncer de cuello uterino. Se espera que este dispositivo reduzca los tratamientos innecesarios y los costes sanitarios asociados.
Objetivo
Cervical cancer (CC) kills a 250,000 people annually, frequently affecting young women, and requires persistent infection with high-risk Human Papillomavirus (hrHPV) for its development. It is preventable, by HPV vaccination and the implementation of population screening programmes, and it is curable if detected and treated early. Despite overwhelming evidence that detection of viral nucleic acids (HPV testing) in cervical cellular samples allows earlier detection of CC as compared to cytology (Pap smear), it is feared that its use as a stand-alone test in CC screening would be responsible for over-diagnosis and over-treatment.
HPV OncoPredict is an innovative diagnostic device (IVD) capable of detecting all oncogenic hrHPV genotypes frequently causing cervical infection as well as allowing to accurate identification those 10% of infected women who are truly at risk of developing cervical cancer. With the use of novel viral biomarkers, HPV OncoPredict, starting from a single self- or clinician-collected cellular sample, will enable women to undergo both primary cervical screening and, if HPV-positive, subsequent triage. HPV OncoPredict will allow HPV testing to reliably replace Pap smears in cervical cancer prevention, as recently recommended by European guidelines, being based on a disruptive technology ahead of any competitor’s product and supported by key opinion leaders.
The HPV testing market is huge (€315 M) with around 100 million tests performed each year. The consortium formed by GeneFirst and Hiantis, both highly innovative companies with patented technologies, has the capacity to bring HPV OncoPredict to success. HPV OncoPredict will not only shape the manner in which we stratify women at risk of developing cervical cancer, but also provide an accurate and cost effective test of disease to benefit patients. More importantly, it will feed into how healthcare systems implement screening strategies to benefit patient pathways.
Ámbito científico
- medical and health scienceshealth sciencespublic health
- natural sciencesbiological sciencesbiochemistrybiomoleculesnucleic acids
- natural sciencescomputer and information sciencessoftwaresoftware development
- medical and health sciencesclinical medicineoncologycervical cancer
- medical and health scienceshealth sciencesinfectious diseasesDNA viruses
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEINST-2-2016-2017
Régimen de financiación
SME - SME instrumentCoordinador
OX14 3DB Abingdon
Reino Unido
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.